UNSPSC 51381909: Oxolamine phosphate

This classification denotes a nonsteroidal antiinflammatory drug C14H19N3O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DMG78UE3PU, chemically known as 1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-phenyl-, phosphate (1:1), but more generally known as oxolamine phosphate, which bears US NIH Compound Identifier 6431771. European Medicines Agency schedules Oxolamine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03577MIG.

Most nations, for tariff and trade purposes, schedule oxolamine phosphate under HS 29349990 and SITC 51579. As of Q4 2014, OXOLAMINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCC1NC(NO1)C2CCCCC2.OP(=O)(O)O.

UNSPSC 51381909 Oxolamine phosphate is a Commodity code that in practice captures pharmaceutical procurement by state and local health agencies, though the recent sourcing record shows a significant mismatch between the code assignment and what is actually being bought. Seminole County, Florida posted an IFB in June 2026 (due July 26, 2023, per the notice date) for naloxone and drug deactivation systems — opioid-overdose reversal medications and harm-reduction equipment — rather than oxolamine phosphate, a cough suppressant. The solicitation calls for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building. Vendors must submit bids electronically, include all shipping and delivery costs, hold workers' compensation and commercial general liability insurance, and comply with E-Verify requirements and drug-free workplace certification. The contract runs two years with a one-year renewal option and includes a three-month probationary termination clause.

Seminole County, Florida is the only recent issuing body visible in the source material for this code. The procurement appears to be funded in part through FEMA, introducing federal compliance layers including Clean Air Act and Federal Water Pollution Control Act adherence. The code shows little documented state and local activity in the oxolamine phosphate space itself; recent opportunities under this Commodity code diverge materially from its nominal scope and do not reflect a clear buying pattern for the drug named in the code assignment.